Case selection for high-energy transurethral microwave thermotherapy

Area of Science:

• Urology
• Minimally Invasive Surgery
• Medical Device Technology

Background:

• Benign prostatic hyperplasia (BPH) is commonly treated with transurethral microwave thermotherapy (TUMT).
• Various TUMT devices and software exist, necessitating an understanding of factors influencing treatment efficacy.
• Identifying predictors of response can optimize patient selection and treatment outcomes.

Purpose of the Study:

• To identify baseline parameters that predict patient response to different transurethral microwave thermotherapy (TUMT) devices.
• To analyze treatment outcomes for three high-energy thermotherapy devices: Urowave, Prostalund, and Prostatron.

Main Methods:

• Retrospective analysis of clinical data from patients treated with Urowave, Prostalund, and Prostatron devices.
• Comparison of baseline parameters (peak flow rate, URA, symptom score) between responders and non-responders at 1-year follow-up.
• Statistical analysis to determine the significance of baseline parameters in predicting treatment response.

Main Results:

• For the Prostatron device, responders showed significantly lower baseline peak flow rate and higher URA, receiving a greater energy dose.
• No significant baseline predictors of response were identified for the Prostalund device.
• For the Urowave device, a significant difference in baseline peak flow rate was observed at 6 months but not at 12 months.

Conclusions:

• Baseline parameters predictive of clinical response were identified only for the Prostatron TUMT device.
• Further research into prostate tissue architecture, vascularity, microwave frequency, applicator design, temperature, and duration is needed.
• Optimizing the use of TUMT requires a deeper understanding of device-specific responses and influencing factors.